Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Permethrin 5% for Demodex-Blepharitis
NCT03105505Phase 4Unknown
- Sponsor
- Barzilai Medical Center
- Start
- Apr 2017
- Primary completion
- Sep 2018
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of permethrin in Demodex blepharitis (DB) (3 arms), sponsored by Barzilai Medical Center. Primary endpoints: Decrease in demodex infestation at 2 months and Improvement in symptoms and complaints at 2 months. Status: unknown.
02
Drugs
permethrin
03
Conditions
Demodex blepharitis (DB)
Beyond the preview
Go deeper on NCT03105505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03105505.